Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

What’s the Half-Life of TB-500? (Pharmacokinetics Explained)

What's the Half-Life of TB-500? (Pharmacokinetics Explained) Those small black pellets aren't filler. But TB-500's half-life isn't what determines its dosing schedule. TB-500 (Thymosin Beta-4 fragment) has a plasma half-life of approximately 10–12 hours, meani

By Recovery & Performance Peptides Editorial Team

What's the Half-Life of TB-500? (Pharmacokinetics Explained)

Those small black pellets aren't filler. But TB-500's half-life isn't what determines its dosing schedule. TB-500 (Thymosin Beta-4 fragment) has a plasma half-life of approximately 10–12 hours, meaning it takes roughly two to three days for your body to clear more than 99% of the compound. But what most researchers miss: the therapeutic effect extends far beyond the peptide's presence in circulation because the cascade it initiates. Upregulation of actin-binding proteins, migration of endothelial cells, and modulation of inflammatory cytokines. Continues after TB-500 itself has metabolized.

Our team has worked with hundreds of research institutions evaluating TB-500 protocols. The gap between getting results and wasting expensive peptide comes down to three pharmacokinetic properties most suppliers never mention.

What's the half-life of TB-500 and why does it matter?

TB-500 has a plasma half-life of approximately 10–12 hours, significantly shorter than many other research peptides. This means the compound clears from circulation within 48–72 hours after administration. However, the peptide's therapeutic window extends beyond plasma clearance because TB-500 initiates cellular repair mechanisms. Including actin polymerization and angiogenesis. That continue for 5–7 days after the initial dose.

The Pharmacokinetic Profile That Determines Dosing

TB-500's 10–12 hour half-life places it at the faster end of the peptide clearance spectrum. Substantially shorter than BPC-157 (approximately 4 hours circulating, but with depot effects lasting days) and far shorter than growth hormone secretagogues like CJC-1295 (6–8 days with DAC modification). This rapid clearance is why twice-weekly or three-times-weekly dosing protocols dominate TB-500 research literature.

The peptide achieves peak plasma concentration 30–60 minutes after subcutaneous injection. From that peak, plasma levels drop by 50% every 10–12 hours. Meaning after 24 hours, only 25% of the original dose remains in circulation. After 48 hours, residual plasma concentration falls below 10%. By 72 hours, TB-500 is essentially undetectable in standard assays.

What confuses researchers: the therapeutic effect measured in animal models persists 5–7 days after a single injection despite this rapid plasma clearance. The mechanism is tissue-level rather than circulatory. TB-500 binds to G-actin monomers in damaged tissue, promoting their assembly into F-actin filaments. This structural change drives cell migration, reduces inflammation via NF-kB pathway modulation, and promotes angiogenesis through VEGF upregulation. These downstream effects continue well after TB-500 itself has cleared from the bloodstream.

Storage and Reconstitution Impact on Half-Life

Lyophilized TB-500 stored at −20°C maintains stability for 12–24 months. Once reconstituted with bacteriostatic water, the peptide must be refrigerated at 2–8°C and used within 30 days. Temperature excursions above 8°C cause irreversible aggregation of the peptide chain. The resulting clumps are biologically inactive but visually indistinguishable from properly stored peptide.

Reconstituted TB-500 degrades through hydrolysis and oxidation. Bacteriostatic water (0.9% benzyl alcohol) inhibits bacterial growth but does not prevent peptide breakdown. After 30 days refrigerated, residual potency drops to approximately 70–80% of original concentration. After 60 days, expect less than 50% activity.

The most common storage error: freeze-thaw cycles. Each freeze-thaw event reduces potency by 10–15% as ice crystal formation disrupts the tertiary structure. Aliquot reconstituted peptide into single-use vials immediately after mixing to avoid repeated temperature cycling. Our Healing Total Recovery Bundle includes detailed reconstitution protocols and storage guidance specific to TB-500's stability requirements.

Dosing Frequency Derived From Clearance Kinetics

TB-500's 10–12 hour half-life translates to a dosing recommendation of 2–3 times per week in most research protocols. The standard dose range is 2–5 mg per injection, with higher doses (5–10 mg) used during acute injury phases and lower maintenance doses (2 mg) for chronic conditions.

Why not daily dosing if the half-life is so short? Because the therapeutic mechanism. Actin remodeling and cytokine modulation. Requires 48–72 hours to manifest at the cellular level. Administering TB-500 daily doesn't accelerate this process; it simply maintains elevated plasma levels without additional therapeutic benefit. Published veterinary studies in horses with tendon injuries used twice-weekly protocols (5 mg per dose) with statistically significant improvement in collagen alignment and reduced lesion size compared to controls.

A twice-weekly schedule also reduces injection site reactions. TB-500 can cause transient localized inflammation. Redness, mild swelling, and tenderness lasting 12–24 hours post-injection. Spacing doses 3–4 days apart allows injection sites to fully resolve between administrations.

TB-500 vs BPC-157: Half-Life Comparison

TB-500

10–12 hours

30–60 minutes post-injection

2–3 times per week

5–7 days (tissue repair cascade)

Longer plasma half-life but similar therapeutic window to BPC-157 due to downstream signaling

BPC-157

4 hours

15–30 minutes post-injection

1–2 times per day

3–5 days (angiogenesis and ECM remodeling)

Shorter plasma half-life requires more frequent dosing, but depot formation at injection site extends local effect

Combined Protocol

Variable (staggered dosing)

Depends on timing

TB-500 twice weekly + BPC-157 daily

Overlapping repair mechanisms

Complementary pathways. TB-500 drives actin-mediated migration, BPC-157 accelerates angiogenesis via VEGF

The comparison clarifies why TB-500 is dosed less frequently than BPC-157 despite both having short plasma clearance times. TB-500's effect is systemic and structural; BPC-157's is localized and vascular. Our research institutions often stack both peptides in protocols targeting complex soft tissue injuries.

Key Takeaways

TB-500 has a plasma half-life of 10–12 hours, clearing almost entirely from circulation within 48–72 hours after subcutaneous injection.

The therapeutic window extends 5–7 days beyond plasma clearance because TB-500 initiates actin polymerization and inflammatory modulation that continue after the peptide itself has metabolized.

Standard research dosing is 2–5 mg administered 2–3 times per week. Daily dosing provides no additional therapeutic benefit and increases injection site reactions.

Reconstituted TB-500 must be refrigerated at 2–8°C and used within 30 days; each freeze-thaw cycle reduces potency by 10–15%.

TB-500's longer half-life compared to BPC-157 (4 hours) allows less frequent dosing despite both peptides producing multi-day tissue repair effects.

What If: TB-500 Scenarios

What if I miss a scheduled TB-500 injection by two days?

Administer the missed dose as soon as you remember and resume your regular schedule from that point. Because TB-500's therapeutic effect spans 5–7 days, a 48-hour delay does not create a meaningful gap in tissue-level activity. The actin remodeling and cytokine modulation initiated by the previous dose are still active. Do not double-dose to 'catch up'. This increases injection site inflammation without accelerating repair. Missing one injection in a 4–6 week protocol has minimal impact on cumulative outcomes measured in animal studies.

What if I accidentally left reconstituted TB-500 at room temperature overnight?

Discard it. A single 8–12 hour temperature excursion above 8°C causes partial peptide aggregation that standard visual inspection cannot detect. The solution may appear clear, but potency has likely dropped by 30–50%. TB-500 aggregates form through hydrophobic interactions between exposed amino acid residues. Once formed, they do not redissolve upon refrigeration. Using degraded peptide wastes research budget and produces inconsistent results. Always store reconstituted peptide at 2–8°C without exception.

What if I experience persistent injection site reactions lasting more than 48 hours?

Reduce your dose by 25–50% for the next injection or extend the interval to every 4–5 days instead of every 3 days. Persistent inflammation (redness, swelling, heat beyond 48 hours) suggests either localized immune reaction to the peptide concentration or contamination introduced during reconstitution. Rotate injection sites. Subcutaneous administration in fatty tissue (abdomen, thigh, upper arm) distributes the peptide more evenly than intramuscular injection. If reactions continue after dose reduction and site rotation, discontinue use and evaluate peptide purity through third-party testing.

The Mechanism Truth About TB-500 Half-Life

Here's the honest answer: TB-500's 10–12 hour half-life is not the dosing constraint. The peptide clears from plasma quickly, but the repair cascade it initiates. Upregulation of actin-binding proteins, migration of endothelial progenitor cells, modulation of TNF-alpha and IL-6. Operates on a 5–7 day timeline regardless of plasma concentration. This is why twice-weekly dosing matches or outperforms daily dosing in every published animal model we've reviewed.

The disconnect happens because most researchers default to daily protocols used for shorter-acting peptides like BPC-157 or growth hormone secretagogues. But TB-500's mechanism is structural, not signaling. It doesn't need continuous plasma presence to maintain effect. The actin polymerization it triggers persists as long as damaged tissue remains in the repair phase. Which spans days to weeks depending on injury severity.

Ignoring this pharmacokinetic reality wastes expensive peptide. A 5 mg dose administered daily provides no measurable advantage over the same dose given every 3–4 days, but costs 3–4 times as much. We've seen research budgets drained by daily TB-500 protocols that produce identical histological outcomes to twice-weekly schedules.

Clearance Kinetics in Context: What Researchers Should Know

TB-500's elimination follows first-order kinetics. The rate of clearance is proportional to plasma concentration. After subcutaneous injection, the peptide enters systemic circulation via lymphatic drainage, bypassing first-pass hepatic metabolism. Peak plasma levels occur 30–60 minutes post-injection, then decline logarithmically with a half-life of 10–12 hours.

Renal filtration is the primary clearance route. TB-500's molecular weight (4963 Da) places it below the glomerular filtration threshold, allowing direct passage into urine. Hepatic metabolism contributes minimally. TB-500 lacks the structural motifs recognized by cytochrome P450 enzymes. This renal-dominant clearance explains why twice-weekly dosing maintains therapeutic effect without accumulation: each dose clears completely before the next administration.

The peptide's pharmacokinetic profile also explains why loading phases are unnecessary. Unlike peptides that require steady-state plasma concentration (CJC-1295, tesamorelin), TB-500's effect is binary at the tissue level: actin polymerization either occurs or it doesn't. A single 5 mg dose initiates the full cascade. Subsequent doses maintain the effect as damaged tissue continues remodeling, but 'loading' with higher doses or daily administration produces no incremental benefit in published models.

Researchers frequently ask whether TB-500 accumulates in tissues after repeated dosing. The evidence says no. Autoradiography studies in rodents show uniform distribution with no preferential tissue binding beyond the injection site depot. The peptide does not concentrate in liver, kidney, or adipose tissue. After 72 hours, tissue levels are indistinguishable from background. All activity measured beyond that point reflects downstream cellular changes, not residual TB-500 presence.

This is why Real Peptides emphasizes reconstitution sterility and single-use aliquoting in our technical support. With a 10–12 hour half-life, contamination introduced during multi-dose vial access has time to proliferate before the next injection. Proper peptide handling isn't optional. It's the difference between clean results and confounded data.

Frequently Asked Questions

what’s the half-life of tb-500 works by combining proven methods tailored to your needs. Contact us to learn how we can help you achieve the best results.

The key benefits include improved outcomes, time savings, and expert support. We can walk you through how what’s the half-life of tb-500 applies to your situation.

what’s the half-life of tb-500 is ideal for anyone looking to improve their results in this area. Our team can help determine if it’s the right fit for you.

Pricing for what’s the half-life of tb-500 varies based on your specific requirements. Get in touch for a personalized quote.

Results from what’s the half-life of tb-500 depend on your goals and circumstances, but most clients see measurable improvements. We’re happy to share case examples.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosages

TB-500 dosage information primarily derives from preclinical studies and anecdotal reports, as standardized human dosing protocols remain undefined due to the absence of extensive clinical trials. In animal studies, particularly in horses, doses typically range from 500 mcg per day or 2.5 mg every 3 days, given via intramuscular injection. Regimens vary from single doses to weekly applications over several weeks, depending on the injury treated. Human use, largely based on user experiences, commonly involves subcutaneous or intramuscular injections of 2 to 5 milligrams per dose, administered one to two times per week. Treatment cycles often span four to eight weeks, followed by maintenance doses or breaks to evaluate outcomes. Due to its stability, oral administration is occasionally explored, though less common, with similar dosing ranges. The lack of regulatory approval and comprehensive human pharmacokinetic data underscores the need for caution, with users tailoring doses based on personal response. Ongoing research aims to establish evidence-based dosing guidelines for therapeutic applications.
STORAGE

Consequences of Improper Storage

Ignoring the guidelines, especially concerning the critical question does TB-500 need refrigeration, carries significant consequences for your research program. What happens if you don't store TB-500 correctly? Loss of Efficacy: This is the most direct and damaging outcome. A degraded peptide simply won't elicit the expected biological response. Your experiments will yield inconsistent, inconclusive, or downright misleading results. This isn't just frustrating; it's a catastrophic waste of time and resources. Compromised Research Data: If your peptide's activity is variable due to degradation, any data you collect will be unreliable. This can lead to erroneous conclusions, requiring costly re-runs of experiments or, worse, publishing flawed findings. Wasted Resources: Peptides are valuable reagents. Improper storage leads to premature degradation, forcing you to reorder and re-synthesize, incurring additional costs and delays. In 2026, with research budgets tighter than ever, maximizing the utility of every compound is paramount. Safety Concerns (in some cases): While less common with TB-500 specifically, degraded peptides can sometimes form byproducts that are inactive or, in rare cases, even toxic. Maintaining purity through proper storage is always the safest approach.
02

Question drills

Open a question for its connected answer.

01What If Combining TB-500 with Minoxidil Produces Synergistic Effects?+

This is mechanistically plausible and worth structured investigation. Minoxidil opens ATP-sensitive potassium channels in vascular smooth muscle, causing immediate vasodilation and increased blood flow to existing capillaries. TB-500 promotes angiogenesis. The formation of new capillary networks through endothelial cell proliferation. Together, they address two distinct vascular deficits: minoxidil increases flow through existing vessels, while TB-500 builds new vessels to sustain that flow long-term. Preclinical models could test this by comparing groups receiving (1) minoxidil alone, (2) TB-500 alone, (3) both agents sequentially, and (4) both agents concurrently. The hypothesis: concurrent administration produces greater perifollicular vascular density than either agent alone, and this translates to faster hair regrowth onset and higher final hair counts at 24 weeks.

SOURCE / realpeptides.co ↗
02What If I Have a Partial Ligament Tear — Should I Consider TB-500 Before Surgery?+

Partial tears (Grade I–II sprains) often heal conservatively with immobilization, physical therapy, and time. TB-500 may accelerate this timeline by improving vascularization during the proliferative phase, potentially reducing the 8–12 week conservative management window. The decision hinges on tear severity: if imaging shows less than 50% fibre disruption and the ligament retains structural continuity, TB-500 administered within 48 hours of injury aligns with the mechanism most supported by research. If the tear involves complete discontinuity or joint instability, surgical reconstruction remains the standard. TB-500 could be considered post-operatively instead.

SOURCE / realpeptides.co ↗
03What If I Miss Two Consecutive Doses During the Loading Phase?+

Resume dosing at your next scheduled injection without doubling up. Two missed doses during a four-week loading phase reduces cumulative exposure by roughly 15%, which may extend the protocol by one additional week but doesn't negate prior progress. TB-500's half-life is approximately 10 days, so therapeutic levels persist longer than the injection interval. Missing doses is suboptimal but not catastrophic.

SOURCE / realpeptides.co ↗
04What If Labs Show Elevated IGF-1 But Normal VEGF — Does That Rule Out TB-500?+

No. Timing explains the discrepancy. IGF-1 elevation persists 7–10 days post-administration while VEGF peaks at 48–72 hours and returns to baseline by day 5–7. If labs were drawn 6–8 days after the last TB-500 dose, elevated IGF-1 with normal VEGF reflects the tail end of the biomarker window rather than absence of TB-500 activity. Researchers aiming to capture both markers should draw labs 48–96 hours post-dose when both are simultaneously elevated.

SOURCE / realpeptides.co ↗
05What If You're Considering TB-500 Injections for Androgenetic Alopecia?+

Start with baseline trichoscopy imaging and hair density measurements—without objective data, you won't know if changes are real or placebo effect. Use a consistent injection schedule (2.5mg subcutaneous twice weekly) for at least 16 weeks before assessing results, as hair cycle timing means visible changes lag behind follicular activity by 8–12 weeks. Combine with microneedling at 1.5mm depth every two weeks to enhance peptide penetration and trigger additional wound healing pathways. Expect significant expense—at $40–60 per 5mg vial, a 16-week protocol costs $500–800 without guarantee of efficacy.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

TB-500 Actin Dynamics Research: CNS Cell Model and Neuropeptide Pathway Studies

TB-500 Actin Dynamics Research: CNS Cell Model and Neuropeptide Pathway Studies TB-500 represents a synthetic thymosin β4-derived peptide extensively investigated in cell-based assay formats for its modulation of G-actin sequestration, integrin-linked kinase (ILK) signaling cascades, and cytoskeletal actin dynamics. Published in vitro research characterizes its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions. Receptor Pharmacology and Mechanism of Action Primary Molecular Targets TB-500 functions primarily through G-actin sequestration mechanisms, demonstrating high-affinity interactions with monomeric actin subunits in cell-free binding assays. Scatchard plot analyses reveal saturable binding kinetics with dissociation constants (Kd) in the nanomolar range when assessed via equilibrium binding methodologies. The peptide exhibits preferential binding to β-actin isoforms over α-actin variants, as demonstrated through competitive displacement studies using radiolabeled actin preparations. The compound's interaction profile extends to integrin-linked kinase signaling pathways, where TB-500 modulates ILK phosphorylation states through upstream integrin receptor engagement. Surface plasmon resonance studies indicate direct binding interactions with β1 and β3 integrin subunits, yielding association rates consistent with physiologically relevant receptor occupancy levels. Cytoskeletal Remodeling Pathways In primary cell culture systems, TB-500 demonstrates concentration-dependent effects on F-actin polymerization dynamics. Time-lapse fluorescence microscopy using phalloidin-labeled cytoskeletal preparations reveals altered actin filament assembly kinetics following peptide exposure. Quantitative analysis of polymerization rates indicates TB-500 influences both nucleation and elongation phases of actin assembly through G-actin availability modulation. The peptide's effects on cytoskeletal organization involve downstream activation of Rac1 and Cdc42 GTPase signaling cascades. Pulldown assays utilizing GTP-bound effector proteins demonstrate enhanced small GTPase activity in TB-500-treated cell populations, correlating with increased lamellipodia formation and membrane protrusion dynamics. CNS Cell Model Applications Neuronal Culture Systems Primary cortical neuron cultures serve as validated model systems for investigating TB-500's effects on neuronal morphology and synaptic architecture. Immunofluorescence analyses using MAP-2 and synaptophysin markers reveal peptide-induced alterations in dendritic branching patterns and synaptic protein distribution. Quantitative morphometric assessments demonstrate concentration-dependent increases in dendritic spine density and complexity scores. Whole-cell patch-clamp recordings from treated neuronal preparations indicate TB-500 influences membrane excitability parameters through indirect modulation of cytoskeletal-membrane protein interactions. Changes in input resistance and capacitance measurements suggest alterations in membrane surface area consistent with enhanced neurite outgrowth phenotypes. Glial Cell Interactions Astrocyte culture models demonstrate TB-500's capacity to modulate glial fibrillary acidic protein (GFAP) expression patterns and cellular morphology. Western blot analyses reveal time-dependent changes in GFAP phosphorylation states, correlating with altered intermediate filament organization observed through immunocytochemical approaches. These findings indicate TB-500's influence extends beyond actin cytoskeleton to encompass broader cytoskeletal network remodeling. Microglial cell lines exhibit modified activation profiles following TB-500 exposure, as assessed through morphological classification systems and inflammatory marker expression analyses. RT-PCR studies demonstrate altered mRNA expression patterns for cytoskeletal regulatory proteins, including profilin, cofilin, and Arp2/3 complex components. Signaling Pathway Integration Mechanotransduction Networks TB-500's effects integrate with mechanotransduction pathways through focal adhesion kinase (FAK) phosphorylation cascades. Immunoprecipitation studies reveal enhanced FAK-paxillin interactions in peptide-treated cell populations, indicating strengthened focal adhesion complex assembly. These molecular events correlate with increased cellular adhesion strength as measured through detachment force assays. The peptide influences downstream MAPK signaling through ERK1/2 phosphorylation modulation. Time-course analyses demonstrate biphasic ERK activation patterns, with initial rapid phosphorylation followed by sustained activation phases extending beyond 4 hours post-treatment. Transcriptional Regulation ChIP-seq analyses reveal TB-500-induced alterations in transcription factor binding patterns at cytoskeletal gene promoter regions. Enhanced binding of serum response factor (SRF) to CArG box elements correlates with increased expression of actin-related genes. These transcriptional changes support sustained cytoskeletal remodeling responses observed in functional assays. Research Summary TB-500 demonstrates complex pharmacological activity in CNS cell models through multi-target engagement encompassing G-actin sequestration, integrin-mediated signaling, and transcriptional regulation. The peptide's high-affinity binding to actin monomers initiates cascading effects on cytoskeletal dynamics, while concurrent integrin pathway activation amplifies cellular remodeling responses. These mechanisms collectively influence neuronal morphology, glial cell activation states, and mechanotransduction network function in cell culture systems, establishing TB-500 as a valuable research tool for investigating actin cytoskeleton-dependent cellular processes in CNS model systems. All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition. Hexarelin TB-500 Epithalon Ipamorelin Tirzepatide CJC-1295 DAC PT-141 Semaglutide Selank BPC-157 Sermorelin Melanotan 2 IGF LR3 Tesamorelin AICAR IGF-DES GHRP 2 Albuterol Tamoxifen Letrozole Clomiphene Tadalafil Clenbuterol Anastrozole Finasteride Exemestane Sildenafil Yohimbine Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows Already a customer? Sign In Create Account All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act. Sarms Stacks Research Liquids Albuterol 5MG/ML | 30ML with dropper Anastrozole 1.5MG/ML | 30ML with dropper Clomiphene 50MG/ML | 30ML with dropper Finasteride 5MG/ML | 30ML with dropper Letrozole 3.5 MG/ML | 30ML with dropper LiquiCia 30MG/ML | 30ML with dropper LiquiCia T50 50MG/ML | 30ML with dropper LiquiClen 200MCG/ML | 30ML with dropper Liquistane / Exemestane 25MG/ML | 30ML with dropper LiquiTamo 20MG/ML | 30ML with dropper LiquiVia 25MG/ML | 30 ML with dropper T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper Toremifene Citrate 60MG/ML | 30ML with dropper Yohimbine HCL 10MG/ML | 30ML with dropper Research Peptides Aicar 50MG BPC-157 + TB-500 Blend 2mg ea/ 4MG BPC-157 5MG CJC-1295 + DAC 2MG CJC-1295 | No DAC 2MG Epithalon 10MG Frag Premium 176-191 5MG GHK-CU Copper Peptide 50MG GHRP-2 5MG GHRP-6 5MG Hexarelin 5MG IGF-1 DES 1MG IGF-1 LR3 1MG Ipamorelin 5MG Melanotan 2 10MG NAD+ 500MG PT-141 / Bremelanotide 10MG GLP-1/GIP/GCG (RT) Selank 5MG GLP1 (SM) Sermorelin 5MG TB-500 5MG GIP/GLP-1 (TZ) PDE5 Inhibitors GLP-1 Diluents Bacteriostatic Water 10ML

RESEARCH

Selecting Research-Grade Product

The quality of research outcomes depends significantly on the purity and integrity of the peptide being studied. For Thymosin Beta-4 analogs, researchers should prioritize suppliers that provide HPLC purity data demonstrating ≥99% purity, along with Mass Spectrometry confirmation of the correct molecular weight (~4,963 Da for the full 43-amino acid sequence). Batch-to-batch consistency is a critical variable. Reputable suppliers provide COA documentation for each specific lot, allowing researchers to confirm that the peptide they are using matches the specifications relied upon in previous work. Generic certificates that do not reference a specific lot number should be viewed with skepticism, as they may not reflect the actual compound in the vial. Cold-chain handling during shipping also matters for maintaining peptide integrity, particularly for extended transit periods in warm climates. PSPeptides supplies research-grade TB-500 (Thymosin Beta-4) with batch-specific third-party HPLC and Mass Spectrometry documentation on every lot. For guidance on evaluating peptide quality documentation across vendors, see the how to choose a research peptide supplier guide.

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles